Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia

Active, not recruitingOBSERVATIONAL
Enrollment

2,272

Participants

Timeline

Start Date

April 8, 2010

Primary Completion Date

April 1, 2025

Study Completion Date

June 30, 2025

Conditions
Hereditary Hemorrhagic Telangiectasia
Trial Locations (19)

3435

St. Antonius Hospital, Nieuwegein

21111

HHT Foundation International, Inc., Monkton

21287

Johns Hopkins University School of Medicine, Baltimore

27599

University of North Carolina at Chapel Hill, Chapel Hill, NC

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

55905

Mayo Clinic, Rochester

63110

Washington University School of Medicine, St Louis

72205

University of Arkansas for Medical Sciences, Little Rock

80045

UCHealth Pulmonary Vascular Disease Clinic - Anschutz Medical, Aurora

84132

University of Utah, Salt Lake City

85013

Barrow Neurological Institute, Phoenix

90095

David Geffen School of Medicine at University of California, Los Angeles, Los Angeles

94110

University of California, San Francisco, San Francisco

06520-8042

Yale University, New Haven

30912-3135

Georgia Regents University, Augusta

T6G 2B7

University of Alberta, Edmonton

V6Z 1Y6

St. Paul's Hospital, University of British Columbia, Vancouver

M5B 1W8

St. Michael's Hospital, Toronto

M5G 1X8

Hospital for Sick Children, Toronto

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Unity Health Toronto

OTHER

NCT01158807 - Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia | Biotech Hunter | Biotech Hunter